Gene therapy treatment for AMD in clinical trials

Phase 1 clinical trials on a new gene therapy to treat age-related macular degeneration are currently underway in multiple locations around the country. Early results from the trials are offering promising results and researchers hope gene therapy for wet macular degeneration will be available within the next 3 to 5 years. This new therapy would […]

New Drug Approved for Wet Macular Degeneration

Novartis Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved it’s new drug, BeovuĀ®, for the treatment of wet age-related macular degeneration (AMD). BeovuĀ® (brolucizumab) recently completed two late-stage clinical trials, which tested the safety and efficacy of the intravitreal injection. Wet AMD is an eye condition which can lead to a […]

Medication for Dry Macular Degeneration Coming Soon?

While Wet Macular Degeneration has enjoyed the fruits of great research and effective medications, the more common Dry Macular Degeneration has no similar medications for treatment. That might be changing soon. The company, Allegro Ophthalmics, LLC, has developed the molecule, Risuteganib, which the company states is effective against the oxidative stress in the retina that […]

New implant delivers medicine continuously to eye

The current therapy for treating wet macular degeneration involves costly, frequent injections into the eye. Researchers are currently working on a new therapy that involves putting an implant into the eye that would continuously deliver the medication into the eye. Injection therapy only offers temporary help in preserving central vision with wet macular degeneration and […]

Which medication is best for wet macular degeneration?

Johns Hopkins University School of Medicine researchers studied the ocular as well as systemic effects that three anti-VEGF therapies had on patients. Pegatanib, ranibizumab and bevacizumab were all compared to patients who received no anti-VEGF treatments Researchers evaluated specific studies from databases and focused on 16 randomized controlled trials that had a total of 6347 […]

Will eyedrops replace injections for Macular Degeneration?

Researchers at the University of Birmingham have created a new eyedrop that can deliver wet macular degeneration treatment to the back of the eye. Macular degeneration causes damage to the retina at the back of the eye so this is why it is necessary for the medication to be focused on that area rather than […]

Discontinuing macular degeneration injections results in vision loss

A retrospective, observational study examined the data from 35 patients who had received anti-VEGF injections of the eye for treatment of the wet form of macular degeneration but then stopped treatment despite continued symptoms. Researchers found a notable deterioration in visual acuity over two years. Researchers looked at the best-corrected visual acuity (BCVA) at the […]

Eye injections increase glaucoma risk

Patients who receive seven or more Intravitreous eye injections of bevacizumab (Avastin) each year are at a higher risk of eventually needing glaucoma surgery according to study results recently published in the JAMA Ophthalmology medical journal. Intravitreous injections are the standard therapy for patients suffering from the wet form of macular degeneration. Researchers examined data […]

Endophthalmitis risk greater with intravitreal steroid injections

Endophthalmitis, an inflammation of the internal eye, is a possible complication with any intraocular procedure including intravitreal steroid injections and anti-VEGF injections. A new study found that the risk for developing endophthalmitis after intravitreal steroid injections is nearly seven times greater than the risk after anti-VEGF injections. Prior to the advent of anti-VEGF injections, intravitreal […]

Guess who’s more at risk for recurrent wet macular degeneration?

A retrospective cohort study which reviewed 343 Asian eyes with subfoveal neovascular AMD, which was treated with three monthly anti-VEGF injections of ranibizumab found a link between age and gender and the likelihood of recurrence of the condition. Older men were the patients who required re-treatement within twelve months of their initial treatment. At the […]